Heidelberg Pharma Research GmbH

Heidelberg Pharma AG is a leading biotechnology company specializing in Antibody-Drug Conjugates (ADCs) for the development of innovative cancer treatments. The company's mission is to develop tailored and highly effective therapies for a variety of cancers.

• ADC Technology: Heidelberg Pharma uses ADCs that combine the specificity of antibodies with the efficacy of toxins to target cancer cells. An essential component of this technology is Amanitin from the green death cap mushroom, which is used as an active ingredient in ATAC technology[1][2].
• Product Candidates: The leading development candidates include HDP-101, a BCMA-ATAC for the treatment of Multiple Myeloma, which is in clinical development. The second candidate, HDP-201, is based on Exatecan, a topoisomerase I inhibitor[1][3].
• Partnerships: Heidelberg Pharma works closely with international partners, including Takeda and Binghamton University, to further develop ATAC technology and generate new ADCs[5].

The main mission of Heidelberg Pharma is to provide innovative and effective cancer treatments, especially for therapy-resistant tumors. The goal is to overcome therapy resistance and eliminate even dormant tumor cells by combining antibodies with more potent toxins such as Amanitin[1][2].

Although the information provided does not offer specific details on sustainability goals, the intensive research and development demonstrates sustainable efforts to improve cancer treatment. Heidelberg Pharma focuses on advancing oncology through groundbreaking technologies and collaborations with academic and clinical institutions[5].

The company was founded in September 1997 as Wilex Biotechnology GmbH, originally in Munich. After the acquisition of Heidelberg Pharma GmbH, the headquarters were moved to Ladenburg in 2011 and the company was renamed Heidelberg Pharma AG. Today, the company is listed on the Frankfurt Stock Exchange in the Regulated Market/Prime Standard[3][4].